Caricamento...
Identification of aggregates in therapeutic formulations of recombinant full‐length factor VIII products by sedimentation velocity analytical ultracentrifugation
ESSENTIALS: Factor VIII inhibitors are the most serious complication in patients with hemophilia A. Aggregates in biopharmaceutical products are an immunogenic risk factor. Aggregates were identified in recombinant full‐length factor VIII products. Aggregates in recombinant factor VIII products are...
Salvato in:
| Pubblicato in: | J Thromb Haemost |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5809250/ https://ncbi.nlm.nih.gov/pubmed/29197156 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jth.13917 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|